//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts









Loading...
Today is #CleanAirDay Read our latest Editorial - Clean Air Day: breathe locally, plan globally www.thelancet.com/journals/lan...
From @lancetrespirmed.bsky.social 🫁 The link between 60-day mortality and personalized, best-practice mechanical ventilation in patients with #AcuteRespiratoryDistressSyndrome may be stronger in those with hypoinflammatory vs hyperinflammatory ARDS.
13h
📊 New Article available #OpenAccess 📌Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial 🔗 www.thelancet.com/journals/lan...
📰 New Correspondence: Toxic skies of war "Environmental agencies and health organisations should address war as a dimension of increased environmental risk and hold those responsible to account for the environmental damage caused by warfare actions." www.thelancet.com/journals/lan...
🗞️ News: 2026 #GINA report for #asthma On May 5, 2025, the Global Initiative for Asthma published the 2026 update to their Global Strategy for Asthma Management and Prevention. Check out the major updates here: www.thelancet.com/journals/lan... Written by Priya Venkatesan
🌅 Check out the #SUNRISE phase 3 trial of tezepelumab in reducing OCS use in severe, OCS-dependent #asthma 🟥Efficacy and safety of tezepelumab vs placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent #asthma (SUNRISE) tinyurl.com/6h8xtr8w
💡 New Spotlight: Africa's inhaler dilemma Esther Nakkazi reports on the issues of cost, climate, and care www.thelancet.com/journals/lan...
🏥 June issue of The Lancet Respiratory Medicine available online and in print now! Check out the full issue here: www.thelancet.com/issue/S2213-... 📜 Editorial Clean Air Day: breathe locally, plan globally www.thelancet.com/journals/lan...
🎙️New Podcast Andrew Bush, Heather Zar, and Fernando de Benedictis on how inhaled corticosteroids have changed the treatment of asthma www.thelancet.com/audio-do/and... Check out the full paper here: www.thelancet.com/journals/lan...
13h
1d
16d
16d
6d
6d
15d
11h
Recent reports indicate that the burden of chronic respiratory diseases has increased by 80% in the Middle East and Northern Africa region between 1990 and 2019,1 and air pollution in the region, part...
www.thelancet.com
Sugammadex reduced the incidence of postoperative pulmonary complications or death compared with neostigmine. The risk reduction was small with atelectasis of uncertain clinical significance being the...
www.thelancet.com
Toxic skies of war
Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial
In ARDS, Mortality Risk With Mechanical Ventilation Varies by Phenotype
The link between 60-day mortality and MV in patients with ARDS may be stronger in those with hypoinflammatory vs hyperinflammatory ARDS.
www.pulmonologyadvisor.com
On May 5, 2025, the Global Initiative For Asthma (GINA) published the 2026 update to their Global Strategy for Asthma Management and Prevention. On the same date, an online discussion hosted by GINA p...
www.thelancet.com
2026 GINA report for asthma
When baby Sidrah Isaacs was born, she appeared well. At around 6 weeks of age, her mother, Sasha Leigh, began to notice concerning symptoms, including a silent cough, a weak cry, and breathing difficu...
www.thelancet.com
In this study, tezepelumab treatment led to greater reductions from baseline in daily oral corticosteroid dose than placebo at week 28 despite early study termination. No safety concerns were identifi...
www.thelancet.com
Africa's inhaler dilemma: balancing cost, climate, and care
Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-b...
Inhaled corticosteroids are the foundation of asthma therapy and now, 50 years on from their introduction, is an appropriate time to summarise some of the key studies that have progressed the field. W...
www.thelancet.com
50 years on: how inhaled corticosteroids have changed the treatment of asthma
It's official! The SNaPP trial @anzcactn.bsky.social findings are out, published today @lancetrespirmed.bsky.social, a four year trial with principal investigator @katy-skier.bsky.social.
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine
8d
The Lancet Respiratory Medicine
Pulmonology Advisor
A “hidden pandemic” of lung complications after surgery has been highlighted by an international study led by Australian anaesthetists that has found how a newer muscle relaxant reversal drug can help...
www.anzca.edu.au
Global study highlights hidden pandemic of lung complications - ANZCA
ANZCA